Clinical trial
Temozolomide in Treating Patients With Low-Grade Glioma
NCT00313729 · University of California, San Francisco, Other · Completed
Key facts
| NCT number | NCT00313729 |
|---|---|
| Title | Temozolomide in Treating Patients With Low-Grade Glioma |
| Official title | A Phase II Study of Temozolomide (TEMODAR) in the Treatment of Adult Patients With Supratentorial Low Grade Glioma |
| Lead sponsor | University of California, San Francisco, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | CNS Tumor, Adult |
| Intervention type | Drug |
| Interventions | temozolomide |
| Enrollment | 120 |
| Start date | May 1, 1999 |
| Primary completion | Sep 25, 2014 |
| Completion | Jun 12, 2017 |
| First posted | Apr 12, 2006 |
| Last update posted | Feb 7, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: